Comparative Review of Standardized Incidence Ratio of Nonlymphoid, De Novo Malignancies After Liver Transplant Versus After Kidney Transplant

被引:0
作者
Kim, Andrew [1 ]
Waldron, Olivia [1 ]
Daoud, Deborah [2 ]
Huang, Yihe [3 ]
Patel, Jay [4 ]
Hong, Johnny [5 ]
Butler, Thomas [5 ]
Jain, Ashokkumar [5 ]
机构
[1] Penn State Univ, Coll Med, Hershey, PA USA
[2] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Gen Surg, New Brunswick, NJ USA
[3] Biogen, Cambridge, MA USA
[4] VCU Med Ctr, Dept Cardiothorac Surg, Richmond, VA USA
[5] Penn State Hlth Milton S Hershey Med Ctr, Dept Surg, Div Transplant Surg, Hershey, PA USA
关键词
Cancer; Immunosuppression; Solid organ rejection; Surveillance; RENAL-TRANSPLANTATION; CANCER-RISK; RECIPIENTS; ORGAN; IMMUNOSUPPRESSION; TUMORS; OUTCOMES; THERAPY; HEART;
D O I
10.6002/ect.2024.0136
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Objectives: De novo malignancies are the most common cause of death after solid-organ transplant. Here, we aimed to summarize standard incidence ratios of de novo malignancies after liver and kidney transplant within the same geographical locations, compare these ratios among different types of de novo malignancies after liver and kidney transplant, and elucidate differences in de novo malignancies between liver and kidney transplant recipients. Materials and Methods: We performed a systematic review to identify studies on standard incidence ratios of de novo malignancies after liver and kidney transplant in the United Kingdom, Sweden, South Korea, and Taiwan. Results: Four articles reported standard incidence ratios of de novo malignancies in 14 016 liver transplant recipients (mean follow-up 4.3 +/- 0.7 y) and 48 179 kidney transplant recipients (mean follow-up 6.1 +/- 2.1 y). Mean ratios of oropharyngeal, pulmonary, colorectal, renal, and breast malignancies were 5.3, 1.6, 1.9, 1.8, and 1.1, respectively, after liver transplant and 3.2, 1.7, 1.5, 17.0, and 1.3, respectively, after kidney transplant. Mean ratios of bladder, cervix- uterus, and stomach de novo malignancies were 1.8, 2.0, and 2.9, respectively, after liver transplant and 13.0, 1.9, and 1.9, respectively, after kidney transplant. Mean ratios of prostatic and esophageal malignancies were 1.6 and 1.8 after liver transplant and 1.2 and 1.1 after kidney transplant. Mean ratio of ovarian cancer was 1.2 and 2.9, respectively, after liver and kidney transplant. Conclusions: Low-frequency and lower standard incidence ratios were observed for testicular, ovarian and central nervous system malignancies after kidney and liver transplant. Standard incidence ratios of oropharyngeal and hepatic malignancies were higher after liver transplant compared with kidney transplant. After kidney transplant, standardized ration for renal malignancy were 9.4 times and bladder malignancies were 7.2 times higher compared with liver transplant recipients.
引用
收藏
页码:600 / 606
页数:7
相关论文
共 50 条
  • [11] De-novo malignancies after kidney transplantation: A long-term observational study
    Froehlich, Felix A.
    Halleck, Fabian
    Lehner, Lukas
    Schrezenmeier, Eva V.
    Naik, Marcel
    Schmidt, Danilo
    Khadzhynov, Dmytro
    Kast, Katharina
    Budde, Klemens
    Staeck, Oliver
    PLOS ONE, 2020, 15 (11):
  • [12] De Novo Malignancies After Liver Transplantation With 14 Cases at a Single Center
    Liu, Z. -N.
    Wang, W. -T.
    Yan, L. -N.
    TRANSPLANTATION PROCEEDINGS, 2015, 47 (08) : 2483 - 2487
  • [13] Donor-Transmitted, Donor-Derived, and De Novo Cancer After Liver Transplant
    Chapman, Jeremy R.
    Lynch, Stephen V.
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2014, 12 : 50 - 54
  • [14] De Novo Belatacept in a Kidney-After-Heart Transplant Recipient
    Schenk, Austin D.
    Anderson, Douglas J.
    Cole, Robert T.
    Badell, Idelberto R.
    Larsen, Christopher P.
    TRANSPLANTATION DIRECT, 2020, 6 (01): : E515
  • [15] Kidney transplant performed after liver transplant: a single center experience
    Levine, Matthew H.
    Parekh, Justin
    Feng, Sandy
    Freise, Chris
    CLINICAL TRANSPLANTATION, 2011, 25 (06) : 915 - 920
  • [16] Risk Factors for De Novo Malignancies in Women After Kidney Transplantation A Multicenter Transversal Study
    Helmy, Samir
    Marschalek, Julian
    Bader, Yvonne
    Koch, Marianne
    Schmidt, Alice
    Kanzler, Marina
    Gyoeri, Georg
    Polterauer, Stephan
    Reinthaller, Alexander
    Grimm, Christoph
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 (05) : 967 - 970
  • [17] De Novo Malignancies Screening After Liver Transplantation for Alcoholic Liver Disease: A Comparative Opportunistic Study
    Renaud, Laurence
    Hilleret, Marie-Noelle
    Thimonier, Elsa
    Guillaud, Olivier
    Arbib, Francois
    Ferretti, Gilbert
    Jankowski, Adrien
    Chambon-Augoyard, Christine
    Erard-Poinsot, Domitille
    Decaens, Thomas
    Boillot, Olivier
    Leroy, Vincent
    Dumortier, Jerome
    LIVER TRANSPLANTATION, 2018, 24 (12) : 1690 - 1698
  • [18] De novo malignancies after liver transplantation: a single-center experience
    Hegab, Bassem
    Khalaf, Hatem
    Allam, Naglaa
    Azzam, Ayman
    Al Khail, Faisal Aba
    Al-hamoudi, Waleed
    Kamel, Yasser
    Al Bahili, Hamad
    Al Sofayan, Mohammed
    Al-Sebayel, Mohammed
    ANNALS OF SAUDI MEDICINE, 2012, 32 (04) : 355 - 358
  • [19] De Novo Inflammatory Bowel Disease After Pediatric Orthotopic Liver Transplant: A Case Report
    Dehghani, Seyed Mohsen
    Eshraghian, Ahad
    Bahador, Ali
    Kakaei, Farzad
    Geramizadek, Bita
    Malek-Hosseini, Seyed Ali
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2009, 7 (03) : 145 - 148
  • [20] Fatigue After Liver Transplant and Combined Liver and Kidney Transplant
    Benzing, Christian
    Krenzien, Felix
    Krezdorn, Nicco
    Wiltberger, Georg
    Hinz, Andreas
    Foerster, Julia
    Atanasov, Georgi
    Schmelzle, Moritz
    Glaesmer, Heide
    Hau, Hans Michael
    Bartels, Michael
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2017, 15 (04) : 437 - 444